Powered by

Concordia International Corp. Comments on CMA Statement of Objections Related to Hydrocortisone 10mg

Mar 03, 2017 - PR Newswire

Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today commented on the issuance by the UK Competition and Markets Authority (CMA) of a Statement of Objections to Actavis UK (formerly Auden Mckenzie) and Concordia's International segment in relation to the supply of 10mg hydrocortisone tablets in the United Kingdom between 2013 and 2016. 

A statem...